PT3260136T - Anticorpos de neutralização do vírus da imunodeficiência humana (hiv) - Google Patents
Anticorpos de neutralização do vírus da imunodeficiência humana (hiv)Info
- Publication number
- PT3260136T PT3260136T PT171735483T PT17173548T PT3260136T PT 3260136 T PT3260136 T PT 3260136T PT 171735483 T PT171735483 T PT 171735483T PT 17173548 T PT17173548 T PT 17173548T PT 3260136 T PT3260136 T PT 3260136T
- Authority
- PT
- Portugal
- Prior art keywords
- hiv
- immunodeficiency virus
- human immunodeficiency
- neutralizing antibodies
- neutralizing
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16101009P | 2009-03-17 | 2009-03-17 | |
US16582909P | 2009-04-01 | 2009-04-01 | |
US22473909P | 2009-07-10 | 2009-07-10 | |
US28566409P | 2009-12-11 | 2009-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3260136T true PT3260136T (pt) | 2021-02-12 |
Family
ID=42668183
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT107228108T PT2408476T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
PT182077073T PT3542817T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
PT171735483T PT3260136T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus da imunodeficiência humana (hiv) |
PT171948342T PT3323427T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT107228108T PT2408476T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
PT182077073T PT3542817T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT171948342T PT3323427T (pt) | 2009-03-17 | 2010-03-17 | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) |
Country Status (15)
Country | Link |
---|---|
US (7) | US9051362B2 (pt) |
EP (5) | EP2408476B1 (pt) |
AU (5) | AU2010226668B2 (pt) |
CA (2) | CA2755821C (pt) |
CY (1) | CY1121323T1 (pt) |
DK (1) | DK2408476T3 (pt) |
ES (4) | ES2848203T3 (pt) |
HR (1) | HRP20180027T1 (pt) |
HU (1) | HUE036031T2 (pt) |
LT (1) | LT2408476T (pt) |
NO (1) | NO2408476T3 (pt) |
PL (4) | PL2408476T3 (pt) |
PT (4) | PT2408476T (pt) |
SI (4) | SI3260136T1 (pt) |
WO (1) | WO2010107939A2 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2623794T3 (es) | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermedios para la preparación de moduladores de receptores tipo toll |
US20110212106A1 (en) * | 2010-01-20 | 2011-09-01 | Institute For Research In Bioscience | Hiv-1 neutralizing antibodies and uses thereof |
WO2011109511A2 (en) * | 2010-03-02 | 2011-09-09 | International Aids Vaccine Initiative | Novel hiv-1 envelope glycoprotein |
SI3556396T1 (sl) | 2010-08-31 | 2022-09-30 | Theraclone Sciences, Inc. | Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV) |
EP2618843B1 (en) * | 2010-09-24 | 2016-12-07 | International Aids Vaccine Initiative | Novel hiv-1 broadly neutralizing antibodies |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2013039792A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogens based on an hiv-1 gp120 v1v2 epitope |
WO2013052095A2 (en) * | 2011-10-03 | 2013-04-11 | Duke University | Vaccine |
EP2788026A4 (en) * | 2011-12-05 | 2015-08-05 | Univ Duke | V1V2 IMMUNOGENIC |
CA2858716C (en) | 2011-12-08 | 2021-10-12 | Peter D. Kwong | Neutralizing antibodies to hiv-1 and their use |
EP2828294A1 (en) * | 2012-03-23 | 2015-01-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
AU2014224049B2 (en) * | 2013-02-28 | 2018-11-29 | Therabiol, Inc. | HIV antigens and antibodies |
US20160130328A1 (en) * | 2013-06-17 | 2016-05-12 | Emory University | Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications |
WO2015048517A1 (en) * | 2013-09-28 | 2015-04-02 | Duke University | Escape mutants |
WO2015127108A1 (en) * | 2014-02-19 | 2015-08-27 | Duke University | Trimeric hiv-1 envelopes compositions and uses thereof |
US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
US11116774B2 (en) | 2014-07-11 | 2021-09-14 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
US9738646B2 (en) | 2014-09-16 | 2017-08-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2016054053A2 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Hiv-1 antibodies and uses thereof (adcc and bispecific abs) |
JP2018527366A (ja) | 2015-09-15 | 2018-09-20 | ギリアード サイエンシーズ, インコーポレイテッド | HIVを処置するためのtoll様レセプターのモジュレーター |
AU2016326738B2 (en) * | 2015-09-24 | 2023-08-31 | Abvitro Llc | HIV antibody compositions and methods of use |
EP3992206A1 (en) | 2015-12-15 | 2022-05-04 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
CN107022027B (zh) * | 2016-02-02 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
CN107033241B (zh) * | 2016-02-03 | 2022-03-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Hiv-1广谱中和抗体及其用途 |
CN110831965B (zh) | 2017-06-21 | 2023-03-07 | 吉利德科学公司 | 靶向hiv gp120和cd3的多特异性抗体 |
US20200172601A1 (en) * | 2017-06-22 | 2020-06-04 | University Of Maryland, Baltimore | Broadly neutralizing antibodies against hiv |
EP3817819A1 (en) | 2018-07-03 | 2021-05-12 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
WO2020082045A1 (en) * | 2018-10-19 | 2020-04-23 | University Of Maryland, College Park | Multispecfic anti-hiv antibodies |
AU2020315598A1 (en) | 2019-07-16 | 2022-03-03 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
WO2021087015A1 (en) * | 2019-10-29 | 2021-05-06 | International Aids Vaccine Initiative | Engineered antibodies to hiv env |
US20210277093A1 (en) * | 2020-03-09 | 2021-09-09 | Adma Biologics, Inc. | Immunotherapeutic compositions and methods of production for coronavirus |
KR20230054456A (ko) | 2020-08-25 | 2023-04-24 | 길리애드 사이언시즈, 인코포레이티드 | Hiv를 표적으로 하는 다중특이적 항원 결합 분자 및 이의 사용 방법 |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022162009A1 (en) | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
WO2022161597A1 (en) * | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
WO2022225875A1 (en) * | 2021-04-19 | 2022-10-27 | The Wistar Institute Of Anatomy And Biology | Sialydase linked hiv antibodies and methods of use |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
EP0547065B1 (en) | 1990-06-29 | 2001-08-29 | Large Scale Biology Corporation | Melanin production by transformed microorganisms |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
EP0794792A1 (en) | 1994-12-02 | 1997-09-17 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
JP4773947B2 (ja) | 2003-01-09 | 2011-09-14 | マクロジェニクス,インコーポレーテッド | 細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系 |
AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
CA2585574A1 (en) * | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
SI3556396T1 (sl) * | 2010-08-31 | 2022-09-30 | Theraclone Sciences, Inc. | Nevtralizacijska protitelesa proti virusu človeške imunske pomanjkljivosti (HIV) |
-
2010
- 2010-03-01 SI SI201032049T patent/SI3260136T1/sl unknown
- 2010-03-17 NO NO10722810A patent/NO2408476T3/no unknown
- 2010-03-17 PT PT107228108T patent/PT2408476T/pt unknown
- 2010-03-17 HU HUE10722810A patent/HUE036031T2/hu unknown
- 2010-03-17 PT PT182077073T patent/PT3542817T/pt unknown
- 2010-03-17 EP EP10722810.8A patent/EP2408476B1/en active Active
- 2010-03-17 PT PT171735483T patent/PT3260136T/pt unknown
- 2010-03-17 EP EP18207707.3A patent/EP3542817B1/en active Active
- 2010-03-17 PT PT171948342T patent/PT3323427T/pt unknown
- 2010-03-17 US US12/726,245 patent/US9051362B2/en active Active
- 2010-03-17 PL PL10722810T patent/PL2408476T3/pl unknown
- 2010-03-17 LT LTEP10722810.8T patent/LT2408476T/lt unknown
- 2010-03-17 CA CA2755821A patent/CA2755821C/en active Active
- 2010-03-17 PL PL18207707.3T patent/PL3542817T3/pl unknown
- 2010-03-17 ES ES17194834T patent/ES2848203T3/es active Active
- 2010-03-17 AU AU2010226668A patent/AU2010226668B2/en active Active
- 2010-03-17 ES ES10722810.8T patent/ES2656234T3/es active Active
- 2010-03-17 SI SI201032112T patent/SI3542817T1/sl unknown
- 2010-03-17 ES ES17173548T patent/ES2848555T3/es active Active
- 2010-03-17 SI SI201031616T patent/SI2408476T1/en unknown
- 2010-03-17 ES ES18207707T patent/ES2916404T3/es active Active
- 2010-03-17 EP EP17173548.3A patent/EP3260136B1/en active Active
- 2010-03-17 EP EP22171792.9A patent/EP4085925A1/en active Pending
- 2010-03-17 DK DK10722810.8T patent/DK2408476T3/en active
- 2010-03-17 EP EP17194834.2A patent/EP3323427B1/en active Active
- 2010-03-17 PL PL17173548T patent/PL3260136T3/pl unknown
- 2010-03-17 CA CA2980883A patent/CA2980883C/en active Active
- 2010-03-17 PL PL17194834T patent/PL3323427T3/pl unknown
- 2010-03-17 WO PCT/US2010/027695 patent/WO2010107939A2/en active Application Filing
- 2010-03-17 SI SI201032062T patent/SI3323427T1/sl unknown
-
2015
- 2015-04-21 US US14/692,483 patent/US9920111B2/en active Active
- 2015-10-01 AU AU2015234345A patent/AU2015234345C1/en active Active
-
2017
- 2017-11-20 AU AU2017264985A patent/AU2017264985B2/en active Active
-
2018
- 2018-01-08 HR HRP20180027TT patent/HRP20180027T1/hr unknown
- 2018-01-15 CY CY20181100043T patent/CY1121323T1/el unknown
- 2018-03-12 US US15/918,343 patent/US10239934B2/en active Active
-
2019
- 2019-02-14 US US16/275,936 patent/US10407493B2/en active Active
- 2019-07-17 US US16/513,859 patent/US10865234B2/en active Active
-
2020
- 2020-07-30 AU AU2020210242A patent/AU2020210242B2/en active Active
- 2020-10-28 US US17/082,322 patent/US11584789B2/en active Active
-
2023
- 2023-01-06 US US18/150,957 patent/US20230295278A1/en active Pending
- 2023-06-26 AU AU2023204017A patent/AU2023204017A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2408476T (pt) | Anticorpos de neutralização do vírus de imunodeficiência humana (hiv) | |
AU2016202543A1 (en) | Human immunodeficiency virus (hiv)-neutralizing antibodies | |
PL3556396T3 (pl) | Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv) | |
HK1212935A1 (zh) | 廣譜中和抗 抗體 | |
EP2380976A4 (en) | HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS | |
HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
AP2925A (en) | Inhibitors of human immunodeficiency virus replication | |
DK3329772T3 (da) | Dobbeltvektor til inhibering af human immundefektvirus | |
ZA201202116B (en) | Neutralizing antibodies to hiv-1 and their use | |
EP2618843A4 (en) | NEW ANTIBODIES WITH EXCESSIVE HIV-1 NEUTRALIZATION | |
EP2542703A4 (en) | NEW HIV-1 ENVELOPE GLYCOPROTEIN | |
ZA201002445B (en) | Hiv preventive vaccine based on hiv specific antibodies | |
ZA201207030B (en) | Hiv vaccine | |
IL212311A0 (en) | Immunoenhancer-linked oligomeric hiv vaccines | |
EP2571523A4 (en) | REACTIVATION OF THE HUMAN IMMUNODEFICIENCY VIRUS IN THE LATENT STATE | |
AP2013007180A0 (en) | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto | |
EP2635300A4 (en) | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) | |
GB0912950D0 (en) | Virus | |
EP2542252A4 (en) | HIV-1 CASE-BASED FRAGMENTS | |
ZA201302639B (en) | Antibodies for the treatment of hiv | |
PL2643460T3 (pl) | Sposoby, kompozycje i zestawy do oznaczania ludzkiego wirusa niedoboru odporności (HIV) | |
ZA201105357B (en) | Splitting gp41 | |
GB0901056D0 (en) | Virus | |
HK1177692A1 (zh) | 新的流感病毒 | |
AP3595A (en) | Novel gp41 antigens |